Report Code: A10494 | Pages: NA | Mar 2023 | 1443 Views | ||
Author(s) : NA | Tables: NA | Charts: NA |
|
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Fondaparinux Market
Request Now !Fondaparinux (Arixtra) is a synthetic anticoagulant based on the pentasaccharide sequence that makes up minimal antithrombin (AT) binding region of heparin. Similar to low molecular weight heparins, it is an indirect inhibitor of factor Xa, but it does not inhibit thrombin at all. Fondaparinux has a longer half-life than heparin and does not interact with platelets, both of which may be advantageous in certain settings. Indications for fondaparinux includedeep vein thrombosis and pulmonary embolism and superficial vein thrombosis.It is the same sequence as UFH and LMWH for the binding to antithrombin, however it has no extra chain and thus, is not considered a heparin product. It is also known to not cause HIT, as seen with UFH and LMWH.
Market scope and structure analysis:
Report Metric | Details |
Market size available for years | 2020–2027 |
Base year considered | 2020 |
Forecast period | 2021–2027 |
Forecast units | Value (USD) |
Segments covered | Type, Route of Administration, End User,and Region |
Regions covered | North America (U.S. and Canada), Europe (Germany, UK, France, and Rest of Europe), Asia Pacific (China, Japan, India, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of LATAM) and The Middle East and Africa |
Companies covered | Major players analyzed includeBayer Healthcare AG, GlaxoSmithKline plc., Boehringer Ingelheim, Sanofi S.A., Apotex, Abbott India Limited, Aspen Holdings, Pfizer Inc., Bristol-Myers Squibb Company, Eisai Inc., WisMed Pharmaceuticals and Kaifeng Pharmaceutical. |
Â
COVID-19 scenarioanalysis:
Pharmaceutical and biotechnological companies together with governments around the globe are working to combat the COVID-19 outbreak. This is carried out by supporting development of vaccines to schedule for medicines supply chain challenges. Furthermore, there are around 115 vaccine candidates and other 155 molecules that are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have seen huge boost in demand for management of COVID-19. There is an increase in demand for the drug, which has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are short of the drug. Hence, owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is anticipated to witness a substantial growth in the next few years.
Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis
The major factor affecting the industry includes surge in product developments such that it meets the requirement posed by the market, which would help the industry in the coming years.Majority of key players are investing in product innovations and launching newer products that are cost efficient and hence are expected to help the industry gain traction during the forecast period. Furthermore, companies are focusing in mergers and acquisitions so that they are able to increase distribution channels across various regions, which is anticipated to boost the market growth.
Growth in number of product launches to boost the market
Growth in number of product launches would help the industry flourish during the forecast period. For instance, in December 2017, Aurobindo Pharma received final approval from US health regulators to manufacture and market its generic version of Fondaparinux Sodium injection used to prevent deep vein thrombosis. The approval by US Food & Drug Administration (USFDA) is for multiple strengths of Fondaparinux Sodium injection of 2.5 mg/0.5 mL, 5 mg/0.4 mL, 7.5 mg/0.6 mL, and 10 mg/0.8 mL single-dose prefilled syringes. This is the 52nd ANDA (including 2 tentative approvals) to be approved out of Unit IV formulation facility in Hyderabad, India used for manufacturing general injectable and ophthalmic products
Surge in number of mergers and acquisitions to propel the market
Increase in number of mergers and acquisitions is anticipated to help the industrygrow in the coming years. For instance, in September 2020, Mylan's planned a megamerger with Pfizer's Upjohn generics unit. Mylan will shell out $756 million for European rights to a suite of Aspen Pharmacare's sterile injectable anticoagulants that ranked in nearly a quarter-billion dollars.The Aspen acquisition will position Mylan as one of the largest producers of thrombosis products in Europe. This would help the market to gain traction during the forecast period.
Key segments covered:
Segments | Subsegments |
Type |
|
Route of Administration |
|
End Users |
|
Key benefits of the report:
Questions answered in the Fondaparinuxmarket research report:
Fondaparinux Market Report Highlights
Aspects | Details |
---|---|
By Type |
|
By Route of Administration |
|
By End User |
|
By Region |
|
Key Market Players | Bayer Healthcare AG,, GlaxoSmithKline plc.,, Boehringer Ingelheim,, Sanofi S.A.,, Apotex,, Abbott India Limited,, Aspen Holdings,, Pfizer Inc.,, Bristol-Myers Squibb Company,, Eisai Inc.,, WisMed Pharmaceuticals, Kaifeng Pharmaceutical. |
Loading Table Of Content...
Start reading.
This Report and over 19,614+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers